Authors Kateryna Karpoff and Omar Alani have no conflicts of interest to declare. Dr. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Added Health, Aikium, Almirall, AltruBio Inc., Alumis, Amgen, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Moonlake, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sunpharma, Takeda, Trevi, and Verrica. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Karpoff et al. (Thu,) studied this question.